See how we are responding to the COVID-19 outbreak.

Newtec Vascular Products


Newtec is a medical device company committed to improving the lives of people through developing innovative solutions to meet evolving clinical needs. The business was established to develop innovative medical devices for niche markets in vascular and cardiovascular surgery.

Deal size




Funding need

Product Development


Science Technology

We are extremely pleased to have received funding from NPIF/Maven. Newtec is now well resourced to accelerate the development of its innovative vascular devices including FloGuardian, a novel device for controlling scar tissue formation in vascular surgery to improve outcomes for vascular grafts.

Rob Carson
CEO of Newtec

Growth Journey

 Newtec has created products that address challenges in the cardiovascular market and has designed a suite of unique vascular products, noting complications in all other systems and aiming to eradicate them. The company has also identified further applications for their products with the potential for expanding the product range or out-licensing opportunities.

Within the Cardiovascular device market, Newtec’s product mix is of high commercial interest and has a market value worth billions. Newtec are successfully developing products in a multi-billion-dollar sector which is growing at 8% per year. The growth in this market can primarily be attributed to the rapidly increasing obese population, the high prevalence of cardiovascular diseases across the globe and increase in longevity and ageing population. 

The funding secured will be used to launch a new medical product that has been designed by surgeons, for surgeons.

Could NPIF Maven Equity Finance help fund your growth journey?

If you’re running a business that’s looking to grow, we’d love to hear from you. Feel free to give us a call to find out more about our flexible funding solutions:

0191 731 8595

Subscribe for email updates

Keep up-to-date with all the latest news and insights from Maven,
including new investments, events and our blog.